Literature DB >> 12819202

The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands.

Mathias Färnegårdh1, Tomas Bonn, Sherry Sun, Jan Ljunggren, Harri Ahola, Anna Wilhelmsson, Jan-Ake Gustafsson, Mats Carlquist.   

Abstract

The structures of the liver X receptor LXRbeta (NR1H2) have been determined in complexes with two synthetic ligands, T0901317 and GW3965, to 2.1 and 2.4 A, respectively. Together with its isoform LXRalpha (NR1H3) it regulates target genes involved in metabolism and transport of cholesterol and fatty acids. The two LXRbeta structures reveal a flexible ligand-binding pocket that can adjust to accommodate fundamentally different ligands. The ligand-binding pocket is hydrophobic but with polar or charged residues at the two ends of the cavity. T0901317 takes advantage of this by binding to His-435 close to H12 while GW3965 orients itself with its charged group in the opposite direction. Both ligands induce a fixed "agonist conformation" of helix H12 (also called the AF-2 domain), resulting in a transcriptionally active receptor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819202     DOI: 10.1074/jbc.M304842200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Multiple-step virtual screening using VSM-G: overview and validation of fast geometrical matching enrichment.

Authors:  Alexandre Beautrait; Vincent Leroux; Matthieu Chavent; Léo Ghemtio; Marie-Dominique Devignes; Malika Smaïl-Tabbone; Wensheng Cai; Xuegang Shao; Gilles Moreau; Peter Bladon; Jianhua Yao; Bernard Maigret
Journal:  J Mol Model       Date:  2008-01-03       Impact factor: 1.810

2.  Shoot-and-Trap: use of specific x-ray damage to study structural protein dynamics by temperature-controlled cryo-crystallography.

Authors:  Jacques-Philippe Colletier; Dominique Bourgeois; Benoît Sanson; Didier Fournier; Joel L Sussman; Israel Silman; Martin Weik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

3.  Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism.

Authors:  Yu Xue; Esther Chao; William J Zuercher; Timothy M Willson; Jon L Collins; Matthew R Redinbo
Journal:  Bioorg Med Chem       Date:  2006-12-20       Impact factor: 3.641

4.  Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.

Authors:  Yoshitomo Hamuro; Stephen J Coales; Jeffrey A Morrow; Kathleen S Molnar; Steven J Tuske; Mark R Southern; Patrick R Griffin
Journal:  Protein Sci       Date:  2006-07-05       Impact factor: 6.725

5.  Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR.

Authors:  Matthew D Krasowski; Ai Ni; Lee R Hagey; Sean Ekins
Journal:  Mol Cell Endocrinol       Date:  2010-07-06       Impact factor: 4.102

Review 6.  Nuclear receptors as drug targets for metabolic disease.

Authors:  Ira G Schulman
Journal:  Adv Drug Deliv Rev       Date:  2010-07-22       Impact factor: 15.470

7.  Identifying selective agonists targeting LXRβ from terpene compounds of alismatis rhizoma.

Authors:  Chuanjiong Lin; Jianzong Li; Chuanfang Wu; Jinku Bao
Journal:  J Mol Model       Date:  2021-02-22       Impact factor: 1.810

8.  Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.

Authors:  Sayaka Nomura; Kaori Endo-Umeda; Atsushi Aoyama; Makoto Makishima; Yuichi Hashimoto; Minoru Ishikawa
Journal:  ACS Med Chem Lett       Date:  2015-07-13       Impact factor: 4.345

9.  Doubling the size of the glucocorticoid receptor ligand binding pocket by deacylcortivazol.

Authors:  Kelly Suino-Powell; Yong Xu; Chenghai Zhang; Yong-Guang Tao; W David Tolbert; S Stoney Simons; H Eric Xu
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

10.  Intrinsic disorder in nuclear hormone receptors.

Authors:  Matthew D Krasowski; Erica J Reschly; Sean Ekins
Journal:  J Proteome Res       Date:  2008-07-24       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.